• Je něco špatně v tomto záznamu ?

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials

SC. Bell, PJ. Barry, K. De Boeck, P. Drevinek, JS. Elborn, BJ. Plant, P. Minić, E. Van Braeckel, S. Verhulst, K. Muller, D. Kanters, S. Bellaire, H. de Kock, DE. Geller, K. Conrath, O. Van de Steen, K. van der Ent,

. 2019 ; 18 (5) : 700-707. [pub] 20190503

Jazyk angličtina Země Nizozemsko

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028833

BACKGROUND: Several treatment approaches in cystic fibrosis (CF) aim to correct CF transmembrane conductance regulator (CFTR) function; the efficacy of each approach is dependent on the mutation(s) present. A need remains for more effective treatments to correct functional deficits caused by the F508del mutation. METHODS: Two placebo-controlled, phase 2a studies evaluated GLPG2222, given orally once daily for 29 days, in subjects homozygous for F508del (FLAMINGO) or heterozygous for F508del and a gating mutation, receiving ivacaftor (ALBATROSS). The primary objective of both studies was to assess safety and tolerability. Secondary objectives included assessment of pharmacokinetics, and of the effect of GLPG2222 on sweat chloride concentrations, pulmonary function and respiratory symptoms. RESULTS: Fifty-nine and 37 subjects were enrolled into FLAMINGO and ALBATROSS, respectively. Treatment-related treatment-emergent adverse events (TEAEs) were reported by 29.2% (14/48) of subjects in FLAMINGO and 40.0% (12/30) in ALBATROSS; most were mild to moderate in severity and comprised primarily respiratory, gastrointestinal, and infection events. There were no deaths or discontinuations due to TEAEs. Dose-dependent decreases in sweat chloride concentrations were seen in GLPG2222-treated subjects (maximum decrease in FLAMINGO: -17.6 mmol/L [GLPG2222 200 mg], p < 0.0001; ALBATROSS: -7.4 mmol/L [GLPG2222 300 mg], p < 0.05). No significant effects on pulmonary function or respiratory symptoms were reported. Plasma GLPG2222 concentrations in CF subjects were consistent with previous studies in healthy volunteers and CF subjects. CONCLUSIONS: GLPG2222 was well tolerated. Sweat chloride reductions support on-target enhancement of CFTR activity in subjects with F508del mutation(s). Significant improvements in clinical endpoints were not demonstrated. Observed safety results support further evaluation of GLPG2222, including in combination with other CFTR modulators. FUNDING: Galapagos NV. Clinical trial registration numbers FLAMINGO, NCT03119649; ALBATROSS, NCT03045523.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028833
003      
CZ-PrNML
005      
20210114155215.0
007      
ta
008      
210105s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jcf.2019.04.014 $2 doi
035    __
$a (PubMed)31056441
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Bell, Scott C $u Department of Thoracic Medicine, The Prince Charles Hospital and QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. Electronic address: scott.bell@health.qld.gov.au.
245    10
$a CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials / $c SC. Bell, PJ. Barry, K. De Boeck, P. Drevinek, JS. Elborn, BJ. Plant, P. Minić, E. Van Braeckel, S. Verhulst, K. Muller, D. Kanters, S. Bellaire, H. de Kock, DE. Geller, K. Conrath, O. Van de Steen, K. van der Ent,
520    9_
$a BACKGROUND: Several treatment approaches in cystic fibrosis (CF) aim to correct CF transmembrane conductance regulator (CFTR) function; the efficacy of each approach is dependent on the mutation(s) present. A need remains for more effective treatments to correct functional deficits caused by the F508del mutation. METHODS: Two placebo-controlled, phase 2a studies evaluated GLPG2222, given orally once daily for 29 days, in subjects homozygous for F508del (FLAMINGO) or heterozygous for F508del and a gating mutation, receiving ivacaftor (ALBATROSS). The primary objective of both studies was to assess safety and tolerability. Secondary objectives included assessment of pharmacokinetics, and of the effect of GLPG2222 on sweat chloride concentrations, pulmonary function and respiratory symptoms. RESULTS: Fifty-nine and 37 subjects were enrolled into FLAMINGO and ALBATROSS, respectively. Treatment-related treatment-emergent adverse events (TEAEs) were reported by 29.2% (14/48) of subjects in FLAMINGO and 40.0% (12/30) in ALBATROSS; most were mild to moderate in severity and comprised primarily respiratory, gastrointestinal, and infection events. There were no deaths or discontinuations due to TEAEs. Dose-dependent decreases in sweat chloride concentrations were seen in GLPG2222-treated subjects (maximum decrease in FLAMINGO: -17.6 mmol/L [GLPG2222 200 mg], p < 0.0001; ALBATROSS: -7.4 mmol/L [GLPG2222 300 mg], p < 0.05). No significant effects on pulmonary function or respiratory symptoms were reported. Plasma GLPG2222 concentrations in CF subjects were consistent with previous studies in healthy volunteers and CF subjects. CONCLUSIONS: GLPG2222 was well tolerated. Sweat chloride reductions support on-target enhancement of CFTR activity in subjects with F508del mutation(s). Significant improvements in clinical endpoints were not demonstrated. Observed safety results support further evaluation of GLPG2222, including in combination with other CFTR modulators. FUNDING: Galapagos NV. Clinical trial registration numbers FLAMINGO, NCT03119649; ALBATROSS, NCT03045523.
650    _2
$a aplikace orální $7 D000284
650    _2
$a dospělí $7 D000328
650    12
$a aminofenoly $x aplikace a dávkování $x škodlivé účinky $7 D000627
650    12
$a benzoáty $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D001565
650    12
$a benzopyrany $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D001578
650    _2
$a biologická dostupnost $7 D001682
650    _2
$a aktivátory chloridových kanálů $x aplikace a dávkování $x škodlivé účinky $x farmakokinetika $7 D065101
650    12
$a cystická fibróza $x diagnóza $x farmakoterapie $x genetika $7 D003550
650    _2
$a protein CFTR $x genetika $7 D019005
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a monitorování léčiv $7 D016903
650    _2
$a kombinovaná farmakoterapie $x metody $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $7 D009154
650    12
$a chinolony $x aplikace a dávkování $x škodlivé účinky $7 D015363
650    _2
$a respirační funkční testy $x metody $7 D012129
650    12
$a pot $x chemie $x účinky léků $7 D013542
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Barry, Peter J $u Manchester Adult Cystic Fibrosis Centre, Manchester University NHS Foundation Trust, Manchester, UK.
700    1_
$a De Boeck, Kris $u University Hospital Gasthuisberg, Leuven, Belgium.
700    1_
$a Drevinek, Pavel $u Department of Medical Microbiology, Charles University, Motol University Hospital, Prague, Czech Republic.
700    1_
$a Elborn, J Stuart $u Queen's University, Belfast, UK.
700    1_
$a Plant, Barry J $u University College Cork, Cork, Ireland.
700    1_
$a Minić, Predag $u Mother and Child Health Institute of Serbia, Belgrade, Serbia.
700    1_
$a Van Braeckel, Eva $u Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
700    1_
$a Verhulst, Stijn $u Antwerp University Hospital, Edegem, Belgium.
700    1_
$a Muller, Karine $u Galapagos NV, Mechelen, Belgium.
700    1_
$a Kanters, Desirée $u Galapagos NV, Mechelen, Belgium.
700    1_
$a Bellaire, Susan $u Galapagos UBV, Leiden, the Netherlands.
700    1_
$a de Kock, Herman $u Galapagos NV, Mechelen, Belgium.
700    1_
$a Geller, David E $u AbbVie Inc., North Chicago, IL, USA.
700    1_
$a Conrath, Katja $u Galapagos NV, Mechelen, Belgium.
700    1_
$a Van de Steen, Olivier $u Galapagos NV, Mechelen, Belgium.
700    1_
$a van der Ent, Kors $u UMC Utrecht, Utrecht, the Netherlands.
773    0_
$w MED00006892 $t Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society $x 1873-5010 $g Roč. 18, č. 5 (2019), s. 700-707
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31056441 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114155214 $b ABA008
999    __
$a ok $b bmc $g 1609168 $s 1120013
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 18 $c 5 $d 700-707 $e 20190503 $i 1873-5010 $m Journal of cystic fibrosis $n J Cyst Fibros $x MED00006892
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace